Atypical CML BCR-ABL1 Negative — Specialist Diagnosis & Care
Atypical CML is a rare myeloid neoplasm that resembles chronic myeloid leukaemia but lacks the BCR-ABL1 fusion gene. It is classified as an MDS/MPN overlap neoplasm and requires expert molecular diagnosis to distinguish it from other myeloid disorders. Management is guided by molecular findings and fitness for stem cell transplantation.
- BCR-ABL1 Negative — TKIs Not Effective
- Molecular Panel Guides Prognosis
- HMA Therapy Standard Approach
- Expert Haematology Second Opinion Essential
- Annual Incidence
- ~1–2 per million
- Median Age at Diagnosis
- ~73 years
- BCR-ABL1 Status
- Negative (Defining Feature)
- Key Mutations
- SETBP1, CSF3R, NRAS/KRAS
- Risk of AML Transformation
- ~15–40%
Condition Overview
Atypical chronic myeloid leukaemia, BCR-ABL1 negative (aCML) is a rare myeloid neoplasm classified by the 2022 WHO classification as an MDS/MPN overlap syndrome — a group of clonal myeloid disorders exhibiting features of both myelodysplastic syndrome (dysplasia) and myeloproliferative neoplasm (myeloid proliferation). It accounts for fewer than 2–3% of CML-like myeloid neoplasms and is one of the rarest recognised myeloid entities.
The defining diagnostic requirement is the demonstration of leukaocytosis with neutrophilia and dysplastic granulocytes in the absence of the BCR-ABL1 fusion gene, the Philadelphia chromosome (Ph), and PDGFRA/PDGFRB rearrangements. This excludes classic CML, CEL-NOS, and other molecularly defined MPN subtypes. The absence of BCR-ABL1 means tyrosine kinase inhibitors (TKIs) — the foundation of CML therapy — are not effective in aCML.
aCML predominantly affects older adults (median age ~73 years) and carries a poor prognosis, with significant risk of acute myeloid leukaemia (AML) transformation (approximately 15–40% of cases) and a median overall survival of approximately 12–25 months from diagnosis. The disease is molecularly heterogeneous, with recurring mutations in SETBP1, CSF3R, NRAS, KRAS, SF3B1, SRSF2, ETNK1, and others that are being mapped to prognosis and emerging therapeutic targets.
Types and Subtypes
aCML does not have formal WHO-recognised morphological subtypes, but is increasingly stratified by molecular driver mutations that appear to have prognostic and potentially therapeutic significance. Understanding the molecular subtype guides treatment decisions and clinical trial eligibility.
Symptoms and Signs
aCML symptoms reflect the myeloproliferative and myelodysplastic components of the disease — anaemia and cytopaenias from dysplastic marrow failure, alongside leucocytosis and splenomegaly from the myeloproliferative component.
Causes and Risk Factors
aCML arises from clonal transformation of a myeloid progenitor cell acquiring multiple cooperating mutations in signalling, spliceosome, and epigenetic regulator genes. No single defining mutation accounts for all cases. Environmental and lifestyle risk factors are not well established given the rarity of the condition.
Diagnosis and Investigations
aCML is a diagnosis of exclusion — multiple molecularly defined myeloid neoplasms must be rigorously excluded before aCML can be confirmed. WHO 2022 criteria require leucocytosis with dysgranulopoiesis and absence of BCR-ABL1, PDGFRA/PDGFRB, FGFR1 rearrangements, and PCM1-JAK2. A comprehensive molecular panel is essential.
Staging and Risk Stratification
aCML does not have a universally adopted formal staging system equivalent to the ELN CML framework. Disease phase (chronic versus blast phase) and molecular features (particularly SETBP1 mutation) provide the primary prognostic framework used at specialist centres.
Standard Treatment
There is no approved disease-modifying therapy specifically for aCML, and no randomised controlled trial evidence for any single treatment. Management is expert-opinion-based and adapted from MDS/CMML protocols. The principal treatment approaches are hypomethylating agents (HMAs), cytoreductive agents for symptom and count control, and allogeneic stem cell transplantation for fit patients.
Advanced and Emerging Therapies
The rarity of aCML and its molecular heterogeneity have limited formal trial development. However, the discovery of recurring targetable mutations — particularly CSF3R T618I (JAK/STAT) and RAS pathway mutations — is generating rationale for molecularly targeted approaches. CancerFax assists patients in identifying access to emerging therapies and specialist MDS/MPN programmes.
JAK Inhibitor
Ruxolitinib — CSF3R-Mutant aCML
Ruxolitinib (JAK1/2 inhibitor) has demonstrated activity in CSF3R T618I-mutant myeloid neoplasms (CNL and aCML with this mutation) in case reports and small series, consistent with the JAK/STAT pathway activation caused by this mutation. Not approved for aCML; used off-label or in clinical trial settings for CSF3R-positive cases. Formal Phase II data in CSF3R-mutant aCML/CNL support further investigation.
BCL-2 Inhibitor + HMA
Venetoclax + Azacitidine / Decitabine
Venetoclax + HMA has demonstrated activity in higher-risk MDS and CMML — related MDS/MPN overlap neoplasms — and is being evaluated in aCML. In blast phase aCML representing secondary AML, venetoclax + HMA is a meaningful option for patients ineligible for intensive induction. Activity in chronic-phase aCML is uncertain and under investigation.
MEK / RAS Pathway Inhibitor
MEK Inhibitors — RAS-Mutant aCML (Investigational)
Given the high prevalence of RAS pathway mutations (NRAS, KRAS, CBL) in aCML, MEK inhibitors (trametinib, cobimetinib) are of theoretical interest. Early-phase basket trials in RAS-mutant myeloid neoplasms are evaluating MEK inhibitors in CMML and related MDS/MPN overlaps — findings may be relevant to RAS-mutant aCML patients.
Allogeneic Stem Cell Transplantation
Allo-SCT — Only Curative Option
Allo-SCT remains the only potentially curative treatment for aCML. Matched sibling donor, matched unrelated donor, and haploidentical donor transplantation are all potential options depending on patient age, performance status, and donor availability. RIC conditioning extends eligibility. Centre selection at high-volume transplant programmes is important given aCML's rarity.
China and International Trial Access
Novel MDS/MPN Overlap Trials Including aCML
Specialist haematology centres in China (Ruijin Hospital Shanghai, Peking Union Medical College Hospital, West China Hospital) are running MDS/MPN overlap trials that may include aCML patients. Novel agents targeting the epigenetic and RAS pathway vulnerabilities of these neoplasms are being evaluated. CancerFax supports patients in identifying eligibility and access.
Biomarkers and Precision Medicine
Comprehensive molecular profiling is essential in aCML — for differential diagnosis, prognostic stratification, therapeutic target identification, and monitoring. Given the rarity of the disease, molecular findings may guide eligibility for molecularly matched clinical trials.
When to Seek a Second Opinion
aCML is one of the rarest myeloid neoplasms, and most haematologists will have seen very few or no cases. Expert haematopathology and specialist haematology-oncology review is strongly recommended for all newly diagnosed cases and at key decision points during management.
Clinical Trials and Research in aCML
Prognosis and Outcomes
aCML carries a generally poor prognosis, with median overall survival of approximately 12–25 months from diagnosis in published series. Significant heterogeneity exists, driven by molecular features, age, and access to allo-SCT. Honest prognostic discussions with specialist haematology teams are important for treatment planning and advance care decisions.
Supportive Care
Supportive care in aCML manages the consequences of pancytopaenia and myeloproliferation, maintains quality of life during HMA therapy, and prepares patients for transplant where applicable.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with atypical CML by facilitating expert haematopathology second opinions and comprehensive molecular panel review, coordinating specialist MDS/MPN haematology consultations for treatment planning and transplant eligibility assessment, and identifying clinical trial access for molecularly targeted approaches at specialist centres in India, China, and internationally.
Get a free case reviewFrequently Asked Questions
Atypical CML (aCML) is a rare myeloid blood cancer that resembles classic chronic myeloid leukaemia (CML) in its blood count picture — with a high white cell count dominated by granulocytes — but fundamentally differs in that it lacks the BCR-ABL1 fusion gene (the Philadelphia chromosome). This distinction is critical because classic CML is highly effectively treated with TKI drugs (imatinib, dasatinib, etc.) that target the BCR-ABL1 kinase. In aCML, BCR-ABL1 is absent and TKIs have no role. BCR-ABL1 testing is therefore mandatory before diagnosing aCML — a negative result is one of the core diagnostic requirements for this condition.
Atypical CML and chronic myelomonocytic leukaemia (CMML) are both MDS/MPN overlap neoplasms, but they are distinguished by their blood and marrow picture. aCML is characterised by leucocytosis with neutrophilic and dysplastic granulocyte proliferation and relatively few monocytes. CMML by definition has persistent monocytosis (monocytes >1 × 10⁹/L representing >10% of the white cell count). Expert haematopathology and molecular review is essential, as the distinction matters for prognosis, clinical trial eligibility, and treatment selection.
There are no approved targeted therapies specifically for aCML. However, two molecular subsets show potential sensitivity to targeted agents: patients with CSF3R T618I mutations may respond to the JAK1/2 inhibitor ruxolitinib, based on published case reports and a small Phase II study in CSF3R-mutant myeloid neoplasms. Patients with RAS pathway mutations (NRAS, KRAS) may be candidates for MEK inhibitor trials. These approaches are investigational — patients should ideally be enrolled in clinical trials. For all other aCML patients, hypomethylating agents (azacitidine or decitabine) and allogeneic SCT remain the mainstay of treatment.
Hypomethylating agents (HMAs) — azacitidine and decitabine — are the most widely used systemic treatments for aCML, extrapolated from their established benefit in MDS and CMML (related conditions). They work by reversing abnormal DNA methylation that contributes to the dysplastic features of the disease. HMAs can reduce transfusion dependence, control leucocytosis, and may delay AML transformation in responding patients. Formal aCML-specific response rate data are limited, but approximately 30–50% of patients derive some benefit. They are not curative — allo-SCT remains the only treatment with curative potential.
Allogeneic bone marrow or stem cell transplantation (allo-SCT) is the only potentially curative treatment for aCML and should be evaluated for all patients who are fit enough — typically those under approximately 70 years of age with adequate organ function and an available donor. Given the poor prognosis of aCML (median survival 12–25 months) and significant risk of AML transformation, transplant evaluation should be initiated promptly in chronic phase rather than waiting for disease progression. Older patients with significant comorbidities may still be candidates for reduced-intensity conditioning allo-SCT at specialist centres.
A comprehensive myeloid NGS panel should be performed at diagnosis. Key mutations to identify include: SETBP1 (adverse prognosis, AML transformation risk), CSF3R T618I (possible ruxolitinib sensitivity, overlap with CNL), NRAS/KRAS/CBL (RAS pathway, MEK inhibitor trial eligibility), SF3B1/SRSF2/U2AF1 (spliceosome mutations), TET2/DNMT3A/ASXL1 (epigenetic regulators), and TP53 (adverse prognosis, especially in therapy-related cases). These results inform prognosis, clinical trial eligibility, and — in the case of CSF3R T618I — may immediately alter treatment strategy.
Yes. CancerFax supports patients with aCML by reviewing bone marrow biopsy reports and NGS molecular panels, confirming the diagnosis (ensuring BCR-ABL1 and PDGFRA/PDGFRB exclusion), identifying CSF3R or RAS mutation status for targeted therapy eligibility, coordinating specialist haematology second opinions and transplant eligibility assessments, and assisting with access to MDS/MPN overlap clinical trials at specialist centres in India, China, and internationally. Please share your medical reports through the CancerFax portal or contact our team to begin.
Diagnosed With Atypical CML? CancerFax Connects You With Specialist Expertise.
From confirming the molecular diagnosis and identifying targetable mutations to transplant evaluation and clinical trial access, CancerFax supports aCML patients in navigating one of the rarest and most complex myeloid neoplasms.